A carregar...

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours

While current literature provides evidence that imatinib mesylate has significant activity in patients with advanced and metastatic gastrointestinal stromal tumour (GIST), and highlights the potential for the development of anticancer drugs based on specific molecular abnormalities present in cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gauden, Ruth, Gauden, Stan
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2011
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3080786/
https://ncbi.nlm.nih.gov/pubmed/21516270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000327698
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!